trizeptide vs semaglutide 🚨 Breaking News: Real-World Data Comparing and Tirzepatide on Cardiovascular Outcomes Weight loss with semaglutide for

Ethical concerns arise from the lack of long-term safety data, highlighting the need for further research as the side effect profile continues to evolve with broader use

We defined somatic comorbidity as having type 1 and 2 diabetes (ICD-10: E10, E11, E14), obesity (ICD-10: E66), heart disease (ICD-10: I20-I25), stroke (ICD-10: I61, I63, I64, G45) within 10 years prior to index date

Opublikowane w New England Journal of Medicine (2023) badanie II fazy objo 338 dorosych z otyoci lub nadwag, randomizowanych do Retatrutydu 1, 4, 8 lub 12 mg SC tygodniowo albo placebo przez 48 tygodni

This type of weight gain might signal underlying problems such as heart failure, kidney problems, or liver disease, particularly in patients with pre-existing cardiovascular conditions or those taking blood thinners